The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metaboliteAtsuhiro Sugidachi, Fumitoshi Asai, Taketoshi Ogawa et al.|Journal of Thrombosis and Haemostasis|2007Cited by 220
Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal speciesY. Niitsu, Fumitoshi Asai, Atsuhiro Sugidachi et al.|European Journal of Pharmacology|2007Cited by 47
The influence of P2Y12 receptor deficiency on the platelet inhibitory activities of prasugrel in a mouse model: Evidence for specific inhibition of P2Y12 receptors by prasugrelMasami Hashimoto, Fumitoshi Asai, Atsuhiro Sugidachi et al.|Biochemical Pharmacology|2007Cited by 29
Effects of prasugrel, a novel P2Y12 inhibitor, in rat models of cerebral and peripheral artery occlusive diseasesTaketoshi Ogawa, Atsuhiro Sugidachi, Masami Hashimoto et al.|European Journal of Pharmacology|2009Cited by 16
Selective Blockade of P2Y12 Receptors by Prasugrel Inhibits Myocardial Infarction Induced by Thrombotic Coronary Artery Occlusion in RatsAtsuhiro Sugidachi, Y. Niitsu, Shinji Yamaguchi et al.|Journal of Cardiovascular Pharmacology|2011Cited by 15